Novo Nordisk's Focus Remains on Growing Production Capacity -- Market Talk

Dow Jones2023-09-29

0746 GMT - Novo Nordisk's management priorities remain focused on scaling supply-chain capacities and growing the pipeline to sustain growth through the 2030s/40s, Citi analysts say in a note after meeting the company's chief financial officer. There are currently 500,000 U.S. patients on weight-loss drug Wegovy versus an addressable U.S. population of over 100 million and expected global population of 1 billion by 2030, Citi says. "The CFO seemed to be bemused that the warning letter relating to Clayton [manufacturing plant] had generated so much share price volatility. Actions to address FDA concerns have already been made, and the facility continues to run at full capacity." Management believes Medicare access to Wegovy is a matter of when not if, Citi says. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

September 29, 2023 03:46 ET (07:46 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2371703067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-09-29 15:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2371703067","market":"us","top_or_hot":-1,"title":"Novo Nordisk's Focus Remains on Growing Production Capacity -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0746 GMT - Novo Nordisk's management priorities remain focused on scaling supply-chain capacities and growing the pipeline to sustain growth through the 2030s/40s, Citi analysts say in a note after meeting the company's chief financial officer. There are currently 500,000 U.S. patients on weight-loss drug Wegovy versus an addressable U.S. population of over 100 million and expected global population of 1 billion by 2030, Citi says. \"The CFO seemed to be bemused that the warning letter relating to Clayton [manufacturing plant] had generated so much share price volatility. Actions to address FDA concerns have already been made, and the facility continues to run at full capacity.\" Management believes Medicare access to Wegovy is a matter of when not if, Citi says. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 29, 2023 03:46 ET (07:46 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Focus Remains on Growing Production Capacity -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Focus Remains on Growing Production Capacity -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2023-09-29 15:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0746 GMT - Novo Nordisk's management priorities remain focused on scaling supply-chain capacities and growing the pipeline to sustain growth through the 2030s/40s, Citi analysts say in a note after meeting the company's chief financial officer. There are currently 500,000 U.S. patients on weight-loss drug Wegovy versus an addressable U.S. population of over 100 million and expected global population of 1 billion by 2030, Citi says. \"The CFO seemed to be bemused that the warning letter relating to Clayton [manufacturing plant] had generated so much share price volatility. Actions to address FDA concerns have already been made, and the facility continues to run at full capacity.\" Management believes Medicare access to Wegovy is a matter of when not if, Citi says. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 29, 2023 03:46 ET (07:46 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2371703067","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2371703067","pubTimestamp":1695973560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0746 GMT - Novo Nordisk's management priorities remain focused on scaling supply-chain capacities and growing the pipeline to sustain growth through the 2030s/40s, Citi analysts say in a note after meeting the company's chief financial officer. There are currently 500,000 U.S. patients on weight-loss drug Wegovy versus an addressable U.S. population of over 100 million and expected global population of 1 billion by 2030, Citi says. \"The CFO seemed to be bemused that the warning letter relating to Clayton [manufacturing plant] had generated so much share price volatility. Actions to address FDA concerns have already been made, and the facility continues to run at full capacity.\" Management believes Medicare access to Wegovy is a matter of when not if, Citi says. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4007":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","NVO":"诺和诺德"},"translate_title":"诺和诺德的重点仍然是增加产能——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"0746 GMT - Novo Nordisk's management priorities remain focused on scaling supply-chain capacities and growing the pipeline to sustain growth through the 2030s/40s, Citi analysts say in a note after meeting the company's chief financial officer. There are currently 500,000 U.S. patients on weight-loss drug Wegovy versus an addressable U.S. population of over 100 million and expected global population of 1 billion by 2030, Citi says. \"The CFO seemed to be bemused that the warning letter relating to Clayton [manufacturing plant] had generated so much share price volatility. Actions to address FDA concerns have already been made, and the facility continues to run at full capacity.\" Management believes Medicare access to Wegovy is a matter of when not if, Citi says. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 29, 2023 03:46 ET (07:46 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2371703067","isCrawlerRequest":true}